These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28892049)

  • 41. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
    Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
    Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis.
    Park JM; Wu T; Cyr AR; Woodfield GW; De Andrade JP; Spanheimer PM; Li T; Sugg SL; Lal G; Domann FE; Zhang W; Weigel RJ
    Oncogene; 2015 Dec; 34(50):6105-14. PubMed ID: 25772240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells.
    Lakshmanan I; Seshacharyulu P; Haridas D; Rachagani S; Gupta S; Joshi S; Guda C; Yan Y; Jain M; Ganti AK; Ponnusamy MP; Batra SK
    Oncotarget; 2015 Aug; 6(25):21085-99. PubMed ID: 26035354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.
    Price-Schiavi SA; Jepson S; Li P; Arango M; Rudland PS; Yee L; Carraway KL
    Int J Cancer; 2002 Jun; 99(6):783-91. PubMed ID: 12115478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3.
    Funes M; Miller JK; Lai C; Carraway KL; Sweeney C
    J Biol Chem; 2006 Jul; 281(28):19310-9. PubMed ID: 16690615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.
    Taneja P; Maglic D; Kai F; Sugiyama T; Kendig RD; Frazier DP; Willingham MC; Inoue K
    Cancer Res; 2010 Nov; 70(22):9084-94. PubMed ID: 21062982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases.
    Rokutan-Kurata M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Koyama M; Shigeto S; Fujimoto M; Zhang M; Morita S; Date H; Haga H
    Clin Lung Cancer; 2017 Jul; 18(4):e273-e281. PubMed ID: 28065467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
    Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
    Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells.
    Senapati S; Gnanapragassam VS; Moniaux N; Momi N; Batra SK
    Oncogene; 2012 Jul; 31(28):3346-56. PubMed ID: 22105367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
    Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
    Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors.
    Wakefield A; Soukupova J; Montagne A; Ranger J; French R; Muller WJ; Clarkson RW
    Cancer Res; 2013 Jan; 73(2):745-55. PubMed ID: 23149915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
    Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
    Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis.
    Deng X; Li Q; Hoff J; Novak M; Yang H; Jin H; Erfani SF; Sharma C; Zhou P; Rabinovitz I; Sonnenberg A; Yi Y; Zhou P; Stipp CS; Kaetzel DM; Hemler ME; Yang XH
    Neoplasia; 2012 Aug; 14(8):678-89. PubMed ID: 22952421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contribution of CXCL12 secretion to invasion of breast cancer cells.
    Boimel PJ; Smirnova T; Zhou ZN; Wyckoff J; Park H; Coniglio SJ; Qian BZ; Stanley ER; Cox D; Pollard JW; Muller WJ; Condeelis J; Segall JE
    Breast Cancer Res; 2012 Feb; 14(1):R23. PubMed ID: 22314082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upregulation of the splice variant MUC4/Y in the pancreatic cancer cell line MIA PaCa-2 potentiates proliferation and suppresses apoptosis: new insight into the presence of the transcript variant of MUC4.
    Xie K; Zhi X; Tang J; Zhu Y; Zhang J; Li Z; Tao J; Xu Z
    Oncol Rep; 2014 May; 31(5):2187-94. PubMed ID: 24676527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
    Hoenerhoff MJ; Shibata MA; Bode A; Green JE
    Transgenic Res; 2011 Apr; 20(2):247-59. PubMed ID: 20549348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer.
    Mosley JD; Poirier JT; Seachrist DD; Landis MD; Keri RA
    Mol Cancer Ther; 2007 Aug; 6(8):2188-97. PubMed ID: 17699716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
    Chaturvedi P; Singh AP; Moniaux N; Senapati S; Chakraborty S; Meza JL; Batra SK
    Mol Cancer Res; 2007 Apr; 5(4):309-20. PubMed ID: 17406026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.
    Jahan R; Macha MA; Rachagani S; Das S; Smith LM; Kaur S; Batra SK
    Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2538-2549. PubMed ID: 29777904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.